Texas A&M AgriLife Research screened 630,003 protein pairs from about 1,100 human mitochondrial proteins with AlphaFold-Multimer and identified 2,895 likely interactions, more than half not previously reported, giving 85 uncharacterized proteins their first probable partners. The paper appeared in Nature Communications on 25 August 2026 and the institutional release on 5 November. Lab experiments in yeast and human cells confirmed several of the partnerships; most predictions remain untested, and the disease links are potential targets, not established ones. Predictions are shared through the MitoMatch web tool.
Technology: AlphaFold-Multimer
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: AlphaFold-Multimer screened about 630,000 protein pairs; lab experiments in yeast and human cells confirmed several of the predicted partnerships, while the release does not say how many of the 2,895 were tested.
- Still unknown: Only several predictions were confirmed, most remain unverified, the interactions are described as likely rather than established, and disease links are potential targets.
- AI role: AlphaFold-Multimer predicted pairwise interactions among mitochondrial proteins; the predictions were released as the MitoMatch web resource.
Evidence sources: https://www.eurekalert.org/news-releases/1150930
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
RFdiffusion-based de novo binder design and experimental screening produced synthetic proteins that inhibited three bacterial defense systems: Thoeris and Avs1 in Bacillus subtilis assays, and DdmDE in Vibrio cholerae. Five designed proteins inhibited Thoeris and nine inhibited Avs1 in the reported screens. An engineered SBSphiJ phage carrying both anti-Thoeris and anti-Avs1 proteins replicated in B. subtilis cells expressing both defenses. In native V. cholerae O1 El Tor, two of four tested DdmDE binders improved plasmid resistance to clearance.
Technology: RFdiffusion de novo binder design, ProteinMPNN sequence design and AlphaFold2/3 structure-guided candidate scoring
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: RFdiffusion-based de novo binder design and experimental screening produced synthetic proteins that inhibited three bacterial defense systems: Thoeris and Avs1 in Bacillus subtilis assays, and DdmDE in Vibrio cholerae.
- Still unknown: These are laboratory proof-of-concept results in three bacterial defense systems and specific strains; they do not demonstrate therapeutic phage efficacy in animals or humans. Binder success was low relative to the computationally designed candidate sets, and the authors note that a verified binder may not work against homologous defense proteins. The native V. cholerae result was tested for plasmid retention, not general transformation across clinical isolates. The earlier bioRxiv version is the same study and is not a separate record.
- AI role: RFdiffusion generated candidate binder backbones for selected target sites in the Thoeris, Avs1 and DdmDE defense proteins; ProteinMPNN designed sequences and AlphaFold-based co-folding/scoring prioritized candidates for experiments. The selected synthetic binders were tested for defense inhibition, direct interactions and ability to restore phage infection or plasmid retention. The measured anti-defense functions and engineered-phage outcomes are the paper-specific results enabled by AI-guided protein design.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13402655/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The study combines trRosetta-based scaffold hallucination and Rosetta design with ProteinMPNN/LigandMPNN sequence design and AlphaFold structural filtering to create NTF2-like binders for six small-molecule targets. An optimized cortisol binder had a measured dissociation constant of 68 nM. A purified-protein, split-luciferase cortisol sensor showed an estimated response EC50 of 72 nM; this is a sensor response measurement, not the binding-affinity value or a clinical detection limit. The sensor also responded to cortisone and 17-alpha-hydroxyprogesterone, so specificity needs improvement. The March 2026 peer-reviewed paper is the source of record.
Technology: trRosetta-based hallucination; Rosetta; ProteinMPNN/LigandMPNN sequence design; AlphaFold structural filtering
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Designed binders for six small-molecule targets were measured for binding affinity (nanomolar to low micromolar), and a cortisol binder was used to build a biosensor.
- Still unknown: The abstract states no specific limitations.
- AI role: Deep learning combined with physics-based methods generated a protein family with varied designable pocket geometries.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41467-026-70953-8&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Tencent researchers generated antibodies against influenza hemagglutinin, PD-1, PD-L1 and SARS-CoV-2 RBD, followed by phage-display screening and SPR characterization. Anti-SC2RBD-H330 showed neutralization IC50 of 0.42 nM. Screening remained extensive, and some confident epitope predictions failed competition tests. The date represents initial journal publication, preceding the January 19, 2026 version of record; a tFold precursor was posted February 8, 2024.
Technology: tFold System; tFold-Ab; tFold-Ag; AlphaFold-Multimer
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Binding and competition assays on generated antibodies; RBD-antibody neutralization.
- Still unknown: Separate supplements and independent replication not assessed. First-public dates of individual journal experiments were not established by precursor version comparison.
- AI role: Generates CDR sequences and predicts complexes for structure-guided filtering.
Evidence sources: https://www.nature.com/articles/s41467-025-67361-9?error=cookies_not_supported · https://www.biorxiv.org/content/10.1101/2024.02.05.578892v1
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
At Michigan State University, AlphaFold predicted the 3D structure of glycerate kinase in a crop and a heat-loving alga. Replacing three flexible loops with rigid loops from the alga produced a hybrid that remained stable up to 65 °C. The enzyme has not yet been tested in whole plants.
Technology: AlphaFold
Family AlphaFold: profile · models page
Publication: Announcement only · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Announcement only
- Test type: direct test
- Tested: Hybrid glycerate kinase enzymes with three loops replaced by rigid loops from a heat-loving alga were tested in the lab, and one stayed stable up to 65 °C; whole-plant testing has not been done.
- Still unknown: It is not yet known whether the hybrid enzyme improves heat resilience in a whole plant; the page does not say whether the AlphaFold-predicted structures were experimentally validated.
- AI role: AlphaFold predicted the enzyme's 3D structures, which were then used in molecular simulations to identify loops to modify.
Evidence sources: https://deepmind.google/blog/engineering-more-resilient-crops-for-a-warming-climate/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
At the University of Missouri, Zachary Berndsen and Keith Cassidy used AlphaFold to predict the structure of apoB100, the scaffold of LDL particles, and refined it using cryo-electron microscopy data. The result is a cage-like shell with a ribbon belt. The post gives no figures such as resolution and no clinical validation.
Technology: AlphaFold
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Cryo-EM images were refined with AlphaFold2 predictions; the resulting apoB100 structure was compared with more than 200 intramolecular cross-links and showed close agreement, with subnanometre resolution in most regions.
- Still unknown: The article states that clinical applications will take time and the structure's implications are not yet realized; it gives no resolution figures or clinical validation, and the abstract states that resolution is subnanometre only in most regions.
- AI role: AlphaFold2 generated the initial atomic-resolution structure predictions, which were refined against cryo-EM data.
Evidence sources: https://deepmind.google/blog/revealing-a-key-protein-behind-heart-disease/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-024-08467-w&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 48 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
With the Norwegian University of Life Sciences, predicted structures of honeybee vitellogenin were confirmed by electron microscopy in July 2025; AlphaFold 3 helped study its interactions with other molecules. Early evidence suggests breeding times for resilient bees could fall from months to weeks, a still preliminary claim.
Technology: AlphaFold, AlphaFold 3
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: AlphaFold-predicted vitellogenin structures were confirmed by electron microscopy in July 2025, per the post; the linked paper reports a cryo-EM structure of native honey bee vitellogenin, and the breeding-time claim comes from early trials.
- Still unknown: The breeding-time benefit (months to weeks) is preliminary and not cited to a publication, and implications for other egg-laying species are possibilities, not established findings.
- AI role: AlphaFold 3 predicted the vitellogenin structures and helped study how it binds other molecules inside the bee.
Evidence sources: https://deepmind.google/blog/breeding-healthier-and-stronger-honeybees/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41467-025-58575-y&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 12 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
An open AlphaFold2-based hallucination pipeline designs binders with reported experimental success rates of 10-100% across 12 targets, with affinities predominantly in the nanomolar range. The authors also demonstrated effects in cell assays and patient-derived samples; these are experimental results, not established clinical treatments. This entry uses the Nature publication date (27 August 2025); the preprint appeared in 2024.
Technology: BindCraft (AlphaFold2-based design)
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Binders tested experimentally across 12 targets (receptors, allergens, de novo proteins, nucleases) with reported success rates of 10-100%, plus functional assays in patient-derived samples and cell assays.
- Still unknown: The abstract gives no number of designs per target or per-target success rates, and states no limitations.
- AI role: Open-source automated pipeline using AlphaFold2 weights to design binders in one shot, without high-throughput screening.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-025-09429-6&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 454 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
AlphaFold-based structural analysis highlighted a helix-helix-turn-helix subdomain in PHGDH that resembles a TALE homeodomain, prompting tests of a previously unrecognized DNA-binding and transcriptional function. Experiments supported PHGDH binding to promoters and activation of IKKα and HMGB1 in astrocytes, independently of its metabolic enzyme activity. In mouse models and human brain organoids, PHGDH expression promoted amyloid pathology; a blood-brain-barrier-permeable inhibitor of its transcriptional function reduced amyloid pathology and improved measured behavioral deficits in mice.
Technology: AlphaFold structure prediction, followed by structural comparison of the predicted PHGDH fold
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: AlphaFold-based structural analysis highlighted a helix-helix-turn-helix subdomain in PHGDH that resembles a TALE homeodomain, prompting tests of a previously unrecognized DNA-binding and transcriptional function.
- Still unknown: The AlphaFold-derived structural resemblance generated the mechanistic hypothesis; experiments establish the reported PHGDH transcriptional and pathology effects in the tested models. The inhibitor and behavioral effects were tested in mice, not people. Human brain organoid findings are in vitro and do not establish clinical disease causation or treatment efficacy. PHGDH overexpression alone did not reproduce all Alzheimer’s disease features, and no human therapeutic outcome is reported.
- AI role: The researchers inspected AlphaFold-predicted PHGDH structure and identified a helix-helix-turn-helix subdomain resembling a TALE homeodomain, which motivated the hypothesis and targeted mutation tests for DNA binding. AlphaFold did not establish PHGDH function or disease causality; the transcriptional activity and pathology effects were tested through biochemical, cellular, organoid and mouse experiments.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12204802/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 20 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
MIT researchers used FragFold, an AlphaFold-based approach, to predict fragments that bind to and inhibit full-length proteins in E. coli. The researchers experimentally confirmed more than half of its binding or inhibition predictions, including cases without prior structural interaction data.
Technology: FragFold, using AlphaFold
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The researchers experimentally confirmed more than half of its binding or inhibition predictions, including cases without prior structural interaction data.
- Still unknown: The institutional report says more than half of predictions were accurate; this is a study-specific validation result, not a general success rate across proteins or organisms.
- AI role: Researchers computationally fragmented bacterial proteins and used AlphaFold predictions to nominate inhibitory fragments; experiments tested binding and inhibition. The AI supplied structural predictions, not experimental verification.
Evidence sources: https://news.mit.edu/2025/ai-system-fragfold-predicts-protein-fragments-0220
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 15 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The General Expression Transformer (GET) model inferred cell-type-specific transcription-factor motif interactions from regulatory data and nominated a lymphocyte-specific interaction between PAX5 and nuclear-receptor-family factors. AlphaFold multimer modeling and PAX5 proximity-labeling in a B-ALL cell line supported interaction with NR2C2; the leukemia-associated PAX5 G183S variant showed increased PAX5–NR2C2 proximity signal. The variant-specific expression profile was enriched for predicted NR/3 and shared PAX5/NR/3 target genes, suggesting a possible regulatory mechanism for the germline risk variant.
Technology: GET (General Expression Transformer) foundation model for cell-type-specific regulatory grammar; AlphaFold2/AlphaFold Multimer for structural hypothesis assessment
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The General Expression Transformer (GET) model inferred cell-type-specific transcription-factor motif interactions from regulatory data and nominated a lymphocyte-specific interaction between PAX5 and nuclear-receptor-family factors.
- Still unknown: This is a cell-line interaction and expression analysis, not proof that the variant causes leukemia or directly alters disease risk through NR2C2. PAX5–NR2C2 interaction itself was consistent with prior evidence for the paralogue PAX2 and mouse pre-B cells; the specific reported distinction is increased interaction signal with PAX5 G183S and associated transcriptional enrichment. The authors call the disease-driving mechanism possible and identify limitations in cell-state and variant resolution.
- AI role: GET learned regulatory syntax across 213 cell types and used motif co-regulation to predict TF–TF interactions, which nominated PAX5/nuclear receptor family interactions in B cells. Structural modeling prioritized candidate binding interfaces. Researchers then used proximity labeling and mass spectrometry in a B-ALL cell line to compare wild-type PAX5 with the G183S leukemia-risk variant.
Evidence sources: https://www.nature.com/articles/s41586-024-08391-z.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 156 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The PICNIC gradient-boosting model ranked proteins for membership in biomolecular condensates using sequence-pattern and AlphaFold2-derived structural features. To test its predictions, researchers expressed 24 poorly characterized human proteins in U2OS cells: 21 formed mesoscale fluorescent foci, and 18 met the paper’s high-confidence condensate threshold. The experiments mapped examples to cytoplasmic bodies, nuclear bodies, nucleoli or P-bodies; for example, TYW5 and RAD51AP1 showed distinct localization patterns. Across the tested set, the authors found condensate localization was not limited to highly disordered proteins.
Technology: PICNIC, a gradient-boosting machine-learning classifier using protein sequence co-occurrence patterns, sequence complexity/disorder features and AlphaFold2-derived structural features
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: To test its predictions, researchers expressed 24 poorly characterized human proteins in U2OS cells: 21 formed mesoscale fluorescent foci, and 18 met the paper’s high-confidence condensate threshold.
- Still unknown: The experimental test used fluorescently tagged proteins expressed in U2OS cells, so observed localization may depend on expression level, tag, cell type or condition. The study did not establish each protein’s endogenous localization or biological function; the authors explicitly state that condensate localization alone makes no functional claim. Three of 24 proteins did not form detectable mesoscale foci, and three additional results were low-confidence under the paper’s size threshold. This is targeted experimental validation of model-selected candidates, not an independently replicated atlas.
- AI role: PICNIC scored human proteins for likely cellular-condensate membership and selected poorly characterized positive predictions for experimental testing. Its rankings directly guided the 24-protein U2OS localization validation; the model was built to predict condensate members (including clients), not only proteins that self-drive phase separation.
Evidence sources: https://www.nature.com/articles/s41467-024-55089-x.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 52 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A RoseTTAFold2-Lite pipeline combined residue coevolution, deep-learning complex prediction and AlphaFold modelling to screen protein pairs across 19 human bacterial pathogens. In a validation set selected using the deep-learning pipeline, co-immunoprecipitation detected four of six predicted interactions. Three pairs lacked prior direct interaction evidence: E. coli UbiE–YcaR, P. aeruginosa PA4105–PA4106, and P. aeruginosa WbpG–HisF2. The PA4105–PA4106 structural similarity to proteins in 3-thiaglutamate biosynthesis and the WbpG–HisF2 result provide functional hypotheses, not established native-pathogen mechanisms.
Technology: RoseTTAFold2-Lite integrated with direct coupling analysis and AlphaFold complex modelling
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: In a validation set selected using the deep-learning pipeline, co-immunoprecipitation detected four of six predicted interactions.
- Still unknown: The positive interaction evidence comes from heterologous co-immunoprecipitation/pull-down assays, with two independent experiments per positive pair, rather than native-pathogen systems. The validation subset was small (four positives among six AI-selected candidates); most of the thousands of predicted interactions remain untested, and false positives and false negatives are expected. Proposed roles for PA4105–PA4106 and UbiE–YcaR remain hypotheses; this paper does not establish their physiological function or a therapeutic target.
- AI role: RoseTTAFold2-Lite used residue–residue coevolution and predicted complex structures to rank candidate protein pairs in a proteome-wide screen. The authors selected six pairs from the final deep-learning pipeline for co-immunoprecipitation tests; four yielded positive interaction signals. Three were described as lacking previously reported direct interaction evidence, including UbiE–YcaR, PA4105–PA4106 and WbpG–HisF2. The models enabled the experimental target selection; they did not themselves establish physical interactions.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11445079/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 52 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The IsAb2.0 workflow, combining AlphaFold-Multimer complex modeling with FlexddG mutation scoring, proposed five substitutions to improve the binding of humanized J3 nanobody HuJ3 to HIV-1 gp120. Of these, E44R experimentally improved binding (ELISA EC50 1.696 nM) and neutralization relative to HuJ3; the other proposed substitutions did not consistently improve binding, and T99R failed to express. The gain did not restore neutralization to the parental llama J3 level.
Technology: IsAb2.0 antibody-design protocol integrating AlphaFold-Multimer 2.3/3.0, SnugDock, alanine scanning and FlexddG
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Of these, E44R experimentally improved binding (ELISA EC50 1.696 nM) and neutralization relative to HuJ3; the other proposed substitutions did not consistently improve binding, and T99R failed to express.
- Still unknown: This is a single, previously known J3 nanobody humanization/optimization case, not de novo antibody discovery, animal efficacy or clinical evidence. Only one of five proposed mutants improved binding; several predictions failed and the authors note limitations in prediction accuracy and manual steps. E44R remained less potent than parental J3.
- AI role: The protocol modeled the HuJ3–gp120 complex, nominated interface hotspots and computationally ranked five single-residue mutations. Researchers synthesized/tested variants in binding and HIV-1 neutralization assays; the measured E44R improvement is the experimental outcome, while most predictions did not improve performance.
Evidence sources: https://academic.oup.com/bib/article/25/5/bbae445/7758758
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 81 of works of the same type, year and subfield (OpenAlex work metrics, 11 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Researchers at the University of Greifswald resolved how a post-translational modification regulates Bacillus subtilis acetyl-CoA synthetase, a central metabolic enzyme. The study used AI-based structural prediction to explain the molecular mechanism at near-atomic detail.
Technology: AlphaFold2 and AI-assisted structural analysis
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: Test context unspecified in annotation. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: not reported
- Tested: Researchers at the University of Greifswald resolved how a post-translational modification regulates Bacillus subtilis acetyl-CoA synthetase, a central metabolic enzyme.
- Still unknown: The institutional announcement says the regulatory mechanism is evolutionarily conserved and may matter in higher organisms; that implication is not itself a demonstration in those organisms.
- AI role: AlphaFold2 structural predictions supported the researchers' mechanistic interpretation of how the enzyme is regulated; the source describes a collaboration with biochemical and structural experiments, not an AI-only result.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11255334/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 27 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 1/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Researchers used AlphaFold2 to predict structures for 1,483 cytidine deaminases, clustered the predictions and experimentally characterized representatives. The screen identified previously uncharacterized enzymes with high editing efficiency, and CD0208^P52A showed little sequence-context preference across AC/GC/TC/CC motifs, a narrow editing window and relatively low off-target activity. In mammalian cells, its base editor introduced stop codons in single- and multicopy genes without DNA double-strand breaks.
Technology: AlphaFold2 protein-structure prediction, followed by structural clustering of candidate cytidine deaminases
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Researchers used AlphaFold2 to predict structures for 1,483 cytidine deaminases, clustered the predictions and experimentally characterized representatives.
- Still unknown: The base-editing experiments were preclinical cell experiments, not animal or clinical efficacy tests. AlphaFold2 supplied predicted rather than experimentally solved structures. The paper reports multiple promising deaminases; CD0208^P52A is the specific context-independent editor highlighted here. No therapeutic safety or in-vivo delivery claim is implied.
- AI role: AlphaFold2-predicted structures at scale were used to mine and cluster 1,483 putative deaminases; representatives were then selected for experimental characterization in cytosine base editors. The model enabled structure-guided candidate selection; editing outcomes were measured experimentally in mammalian cells.
Evidence sources: https://www.nature.com/articles/s41551-024-01220-8.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 37 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Researchers combined a genetic chemical-proximity platform and experimental screening of 72 Mycobacterium smegmatis protein candidates with machine learning. A Lasso model trained on measured degradation data identified N-terminal disorder propensity as associated with degradation potential and predicted candidate targets among 348 essential proteins conserved between M. smegmatis and M. tuberculosis. Experimentally induced degradation of selected essential M. smegmatis proteins inhibited bacterial growth and, for some targets, potentiated antimicrobial compounds.
Technology: Lasso regression model trained on sequence and structural protein descriptors, including AlphaFold2 confidence and predicted disorder propensity
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Researchers combined a genetic chemical-proximity platform and experimental screening of 72 Mycobacterium smegmatis protein candidates with machine learning.
- Still unknown: Most mechanistic and growth evidence was generated in M. smegmatis, a non-pathogenic model, not in clinical treatment or an animal efficacy study. The machine-learning target predictions for the larger set of 348 essential proteins require orthogonal experimental validation. The study reports that targeted degradation of some proteins inhibits growth and potentiates antimicrobials; this does not establish a deployable drug or clinical benefit. Primary paper source checked; no independent replication assessed.
- AI role: Machine learning connected measured degradation constants from experimentally screened protein substrates to protein sequence/structure features, identifying N-terminal disorder propensity as a predictor of degradation potential; the trained model then ranked candidate targets among essential proteins conserved between M. smegmatis and M. tuberculosis. Experiments—not the model alone—showed degradation and antibacterial phenotypes for selected targets.
Evidence sources: https://www.nature.com/articles/s41467-024-48506-8
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 28 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The OSMES workflow screened AlphaFold-modeled vitamin-B6-dependent enzymes by docking the substrate into active sites and ranking catalytically favorable conformations. It identified human SHMT1/2 as enzymes with hydroxytrimethyllysine-aldolase activity, validated in vitro; mouse Tha1 showed much higher catalytic efficiency, supporting a species difference in the pathway. The authors infer that humans may have lost a dedicated gene, with SHMT activity partly compensating.
Technology: OSMES (One Substrate–Many Enzymes Screening), automated structure-based docking/ranking workflow using AlphaFold models
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: It identified human SHMT1/2 as enzymes with hydroxytrimethyllysine-aldolase activity, validated in vitro; mouse Tha1 showed much higher catalytic efficiency, supporting a species difference in the pathway.
- Still unknown: Enzyme activity was validated in vitro. The claim about loss of a dedicated human gene is an evolutionary inference, not a direct gene-knockout demonstration; the authors note unresolved pathway questions.
- AI role: Ranked candidate enzymes for a specified metabolic reaction using docked substrate conformations and catalytically favorable active-site geometry; guided biochemical testing that verified SHMT1/2 activity.
Evidence sources: https://www.nature.com/articles/s41467-024-47466-3.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 87 of works of the same type, year and subfield (OpenAlex work metrics, 13 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A machine-learning classifier applied to quantitative PPI assay data and AlphaFold-Multimer predictions to prioritize SARS-CoV-2 protein interactions; 15 of 34 high-confidence interactions were not previously listed in IMEx. The team then targeted the NSP10–NSP16 methyltransferase interface in an ultra-large virtual screen. Compound 459 bound NSP10 (MST affinity about 13 μM), reduced NSP10–NSP16 interaction in cells (BRET IC50 9.2 μM), inhibited complex methyltransferase activity by about 50% at 100 μM, and reduced SARS-CoV-2 reporter replication in cells (IC50 39.5 μM).
Technology: Multi-adaptive support-vector-machine (maSVM) classifier for quantitative protein–protein interaction data, coupled with AlphaFold-Multimer complex prediction; VirtualFlow/QuickVina2 and later docking methods performed compound screening
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: A machine-learning classifier applied to quantitative PPI assay data and AlphaFold-Multimer predictions to prioritize SARS-CoV-2 protein interactions; 15 of 34 high-confidence interactions were not previously listed in IMEx.
- Still unknown: The paper reports an experimental small-molecule hit, not a drug or clinical effect. Compound 459 has micromolar affinity and cellular antiviral IC50; authors explicitly state it requires extensive optimization. Methyltransferase inhibition was about 50% at 100 μM in one initial assay; subsequent data include cellular interaction and reporter-replication experiments. The NSP10–NSP16 interface was previously known and had prior virtual screening, but this paper reports a different compound scaffold and tested outcomes; shared target does not make this a duplicate. In vitro and cell assays do not demonstrate efficacy in animals or people.
- AI role: The maSVM algorithm prioritized PPI interactions using quantitative LuTHy binary-assay data and AlphaFold-Multimer predictions, supporting selection and mapping of SARS-CoV-2 interactions, including the NSP10–NSP16 interface and interface hot spots. The drug-like compound hit itself was identified by VirtualFlow and docking against the selected interface, not generated by the classifier. Compound 459 was then experimentally tested for protein binding, interaction disruption, methyltransferase activity and viral replication.
Evidence sources: https://link.springer.com/article/10.1038/s44320-024-00019-8
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 37 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A machine-learning-generated MinE homolog, synMinEv25, restored Min oscillations and wild-type-like cell growth and morphology when substituted for the native minE gene in an E. coli strain lacking minDE. Researchers generated variants with a multiple-sequence-alignment variational autoencoder, used AlphaFold2-based structural scoring to select candidates, and screened them in synthetic-cell mimics before in-vivo testing. The validated variant is a distant homolog with less than 50% sequence identity to E. coli MinE.
Technology: Multiple-sequence-alignment variational autoencoder (MSA-VAE), AlphaFold2 Multimer, and a structure-based divide-and-conquer scoring pipeline
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Researchers generated variants with a multiple-sequence-alignment variational autoencoder, used AlphaFold2-based structural scoring to select candidates, and screened them in synthetic-cell mimics before in-vivo testing.
- Still unknown: This is a proof-of-principle result in one engineered E. coli MinDE system, not a general demonstration that generated proteins can replace natural genes. The paper notes weak correlation between several in-silico scores and individual measured protein properties; it reports one best-performing variant and does not establish applications outside this assay.
- AI role: The MSA-VAE generated MinE homolog sequences; structure-based scoring estimated membrane binding, MinD complex formation and dimerization to prioritize 48 candidates from 4,000 generated sequences. Cell-free synthetic-cell assays identified 14 variants with Min oscillations, and researchers tested these in E. coli; synMinEv25 restored oscillations, growth and morphology. AI generated and prioritized candidates, while wet-lab experiments established function.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10914801/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 23 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
CoSaNN combined neural structure prediction, learned sequence optimization and solubility ranking to design variants of an induced-fit ROK carbohydrate kinase. The authors measured expression, thermal stability and activity in vitro. The paper reports measurable expression for 189 of 348 designs in one table, while the strategy-level counts do not sum to that total; no success-rate claim is made here.
Technology: CoSaNN: AlphaFold2-based conformation modeling, ProteinMPNN sequence design and SolvIT graph neural network ranking
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The authors applied CoSaNN to redesign the Arthrobacter polyphosphate glucokinase ROK kinase and performed expression, thermal-stability and enzyme-activity assays on designed variants. The primary Results table reports 189 designs with detectable soluble expression among 348 listed designs; its strategy counts (119+95+94 plus 40 in another strategy; rows in the prose/table are internally inconsistent) do not reconcile cleanly, so the record does not use a single total as a success-rate denominator.
- Still unknown: The study tests a company-designed enzyme set in vitro; it does not establish industrial deployment. The primary paper’s count inconsistency remains explicitly disclosed.
- AI role: CoSaNN uses deep-learning structure prediction (AlphaFold2), sequence optimization with ProteinMPNN and a learned solubility classifier (SolvIT) to rank enzyme designs for experimental characterization.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10945820/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary PMC full text and PNAS DOI record for CoSaNN-guided glucokinase design, Enzymit affiliations, experimental activity results and the discrepancy in reported design totals..
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Researchers developed a fragmentation strategy for AlphaFold-Multimer and applied it to 62 human protein interactions associated with neurological disorders. Eighteen predicted structures were judged correct or likely correct, and experiments corroborated six previously unreported interfaces: FBXO23–STX1B, STX1B–VAMP2, ESRRG–PSMC5, PEX3–PEX19, PEX3–PEX16 and SNRPB–GIGYF1.
Technology: AlphaFold-Multimer with a protein-fragmentation strategy
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Eighteen predicted structures were judged correct or likely correct, and experiments corroborated six previously unreported interfaces: FBXO23–STX1B, STX1B–VAMP2, ESRRG–PSMC5, PEX3–PEX19, PEX3–PEX16 and SNRPB–GIGYF1.
- Still unknown: The article reports 18 correct or likely correct models among 62 interactions and experimental support for six interfaces; these are not a comprehensive interactome map. AlphaFold-Multimer showed limited specificity and was sensitive to input-fragment length, as the source explicitly notes.
- AI role: AlphaFold-Multimer predicted domain–motif interface structures; researchers tested predictions and used the model-informed fragmentation strategy to prioritize interaction interfaces. Wet-lab assays corroborated six novel contacts, while the tool had limited specificity and performance declined with longer/full-length input sequences.
Evidence sources: https://link.springer.com/article/10.1038/s44320-023-00005-6
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 119 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
AI-predicted structural information helped researchers prioritize previously poorly characterized protein families. Experiments supported a translation-targeting toxin-antitoxin superfamily, TumE–TumA. This is one tested family-level result; the broader proposed families and predicted fold are not hundreds of separately validated discoveries. Native-organism function and general experimental validation across the predicted families remain unestablished.
Technology: AlphaFold structural models and DeepFRI functional prediction
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Selected proteins received laboratory functional validation.
- Still unknown: Independent replication and function of the broader computational candidate set were not assessed.
- AI role: AlphaFold structural models and DeepFRI functional prediction supported the stated study; experimental and interpretive work remained with researchers.
Evidence sources: https://www.nature.com/articles/s41586-023-06622-3 · https://edoc.unibas.ch/entities/publication/5b5fe8a1-910e-4fa9-81a1-c5bceb0297be · https://www.sib.swiss/news/artificial-intelligence-tools-shed-light-on-millions-of-proteins
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Indexed primary publisher Methods and publication metadata, institutional abstract and announcing-institution text; full PDF and supplements not freshly recovered..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The team used AlphaFold2 structure predictions to cluster the deaminase family and found that most proteins in a DddA-like clade were not double-stranded DNA deaminases. The work characterized smaller single-strand-specific deaminases, developed a compact cytidine deaminase suitable for packaging a base editor into one AAV, and demonstrated robust editing by a clade member in soybean.
Technology: AlphaFold2-assisted structure-based protein-family clustering
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The team used AlphaFold2 structure predictions to cluster the deaminase family and found that most proteins in a DddA-like clade were not double-stranded DNA deaminases.
- Still unknown: This paper is an AI-assisted protein-discovery and engineering study; experimental base editing demonstrates the utility of selected deaminases, while therapeutic application remains prospective. The study was followed by a 2024 correction/erratum; the record references the original research article, DOI 10.1016/j.cell.2023.05.041, not the erratum.
- AI role: AlphaFold2 predicted protein structures that enabled structure-similarity clustering of a full deaminase family. The clustering guided discovery of functional diversity and selection of enzymes, which the researchers characterized experimentally and used in cell, animal and plant base-editing tests.
Evidence sources: https://doi.org/10.1016/j.cell.2023.05.041
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 254 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Pharma.AI combined PandaOmics, Chemistry42 and an AlphaFold-predicted structure to identify a hepatocellular-carcinoma target and produce a hit molecule within 30 days of target selection, synthesizing seven compounds. A second round produced a more potent hit; an early Chemical Science study, with no clinical efficacy demonstrated.
Technology: Pharma.AI, PandaOmics, Chemistry42 and AlphaFold
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Selected compounds were synthesized and tested in biological assays: the first hit bound CDK20 (Kd about 9.2 µM) and a second AI-driven round gave a more potent compound with greater antiproliferative activity in liver cancer cells; the abstract describes no in vivo testing.
- Still unknown: The abstract notes AlphaFold predictions have varying confidence, the first hit came from only 7 synthesized compounds, and potency values vary widely; no clinical efficacy is demonstrated.
- AI role: Pharma.AI platforms (PandaOmics, Chemistry42) used AlphaFold-predicted structures to select a liver-cancer target and generate candidate molecules.
Evidence sources: https://www.utoronto.ca/news/researchers-use-ai-powered-database-design-potential-cancer-drug-30-days · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1039/D2SC05709C&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 403 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
After experimentally determining different forms of PINK1, the WEHI group used AlphaFold to model the human protein and its dimer, obtaining structures consistent with experimental results. The predictions also helped interpret how mutations associated with early-onset Parkinson’s may affect dimerization; this does not amount to a validated therapy.
Technology: AlphaFold
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The WEHI group compared an AlphaFold model of human PINK1 dimer with its own experimental structure work and used it to model disease mutations, which it says confirmed their suspicions.
- Still unknown: The article describes no specific limitations of the predictions and says plenty of questions remain.
- AI role: AlphaFold modelled human PINK1 and its dimer and the effect of mutations on dimerisation.
Evidence sources: https://deepmind.google/blog/targeting-early-onset-parkinsons-with-ai/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The predicted-protein-structure archive, maintained with EMBL-EBI, grew from nearly 1 million to over 200 million structures, covering practically all cataloged proteins, with free access and bulk download from Google Cloud. More than 500,000 researchers in 190 countries had already used it. These are predictions, not experimental measurements.
Technology: AlphaFold 2
Family AlphaFold: profile · models page
Publication: Announcement only · Test context: Test context unspecified in annotation. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Announcement only
- Test type: not reported
- Tested: The post gives no accuracy metrics for the new structures; it cites two Nature AlphaFold papers and uses in experiments as evidence.
- Still unknown: The post states no explicit limitations or caveats on prediction accuracy.
- AI role: AlphaFold predicted protein structures added to the AlphaFold Database.
Evidence sources: https://deepmind.google/discover/blog/alphafold-reveals-the-structure-of-the-protein-universe/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 5/5 · Validation 1/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
AlphaFold2 and ColabFold, combined with cryo-tomography and cryo-electron microscopy, produced a model of the human nuclear pore complex (about 30 proteins, about 1,000 copies, 120 MDa) covering over 90% of the complex, versus 46% for previous models. Flexible parts remain unresolved; a complete dynamic model is future work.
Technology: AlphaFold2 and ColabFold
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: The integrative model (AlphaFold2 with cryo-ET and cryo-EM data) was validated against experimental data and covers more than 90% of the NPC core versus 46% for previous models.
- Still unknown: Flexible peripheral parts are not modelled, no quantitative confidence scores are given, and a complete dynamic model is future work.
- AI role: AlphaFold2 and ColabFold predicted protein structures that were assembled into the nuclear pore model.
Evidence sources: https://www.embl.org/news/science/puzzling-out-the-structure-of-a-molecular-giant/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A10.1126/science.abm9506&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 360 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
ColabFold pairs AlphaFold2 or RoseTTAFold with fast MMseqs2 homology search, running free on Google Colab. Beyond benchmark comparisons, the paper reports predicting structures for 1,762 Methanocaldococcus jannaschii proteins in 48 hours on one GPU and using predicted complexes to help determine the 120 MDa human nuclear-pore structure with cryo-electron microscopy. The proteome structures are computational predictions, not experimentally validated structures. The nuclear-pore application overlaps the separate nuclear-pore entry; this is a methodological contribution, not an additional independent biological finding.
Technology: ColabFold (AlphaFold2, RoseTTAFold, MMseqs2)
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Throughput was measured (close to 1,000 structures per day on one GPU) and predicted complexes were used alongside cryo-EM to help determine the human nuclear-pore structure.
- Still unknown: Not reported in the abstract read.
- AI role: AlphaFold2 or RoseTTAFold, paired with MMseqs2 homology search, run free on Google Colaboratory.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41592-022-01488-1&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 9430 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Predicted structures for the human proteome (about 20,000 proteins) and 20 other organisms were published, over 350,000 models in total, hosted free by EMBL-EBI. DeepMind announced an expansion to over 100 million structures. These are predictions that complement experimental methods. Note: the page header says July 22, 2022, but the text calls CASP14 “last December” and the 2022 post refers to it as a 2021 release; date corrected to 2021.
Technology: AlphaFold 2
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Predictions cover 98.5% of human proteins; 58% of residues have a confident prediction and 36% very high confidence. Case studies illustrate possible hypotheses.
- Still unknown: The structures are predictions; the abstract does not report experimental confirmation of new structures.
- AI role: AlphaFold 2 applied at proteome scale, with confidence metrics built on the model.
Evidence sources: https://doi.org/10.1038/s41586-021-03828-1
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 3058 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 5/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
AlphaFold achieved a median GDT score of 92.4 across the target set (about 1.6 Å mean error) and 87.0 on the hardest targets, which organizers judged a solution to the problem of single-protein structures. DeepMind notes that protein complexes and interactions with other molecules remain open challenges.
Technology: AlphaFold 2
Family AlphaFold: profile · models page
Publication: Announcement only · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Announcement only
- Test type: prospective or independent check
- Tested: Blind assessment at CASP14 on recently determined protein structures: median GDT of 92.4 across targets and 87.0 on the hardest free-modelling targets, judged by the organizers as a solution to single-protein structure prediction.
- Still unknown: Protein complexes, interactions with DNA, RNA or small molecules, and full side-chain placement remain open; not every predicted structure will be perfect.
- AI role: Attention-based neural network using evolutionary sequence alignments and residue-pair representations to predict 3D protein structure from sequence.
Evidence sources: https://deepmind.google/blog/alphafold-a-solution-to-a-50-year-old-grand-challenge-in-biology/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 5/5 · Validation 4/5 · Novelty 5/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
DeepMind openly shared AlphaFold predictions, without waiting for review, for six poorly studied viral proteins (membrane, ORF3a, Nsp2, Nsp4, Nsp6, and the C-terminal domain of papain-like protease). They were not experimentally verified; an ORF3a experimental structure deposited in the PDB in June 2020 matched the second predicted model well.
Technology: AlphaFold
Family AlphaFold: profile · models page
Publication: Announcement only · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Announcement only
- Test type: prospective or independent check
- Tested: Predictions compared with experimental structures: the spike prediction matched the PDB structure, and the second-ranked ORF3a model agreed well with later experimental work.
- Still unknown: Predictions were not experimentally verified overall; the system was still in development and accuracy is not certain; released before peer review; the top ORF3a model misplaced some transmembrane helices.
- AI role: AlphaFold free-modelling predicted structures for six understudied SARS-CoV-2 proteins, with per-residue confidence scores.
Evidence sources: https://deepmind.google/blog/computational-predictions-of-protein-structures-associated-with-covid-19/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.